Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this podcast, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this lecture library, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
Stroke prevention continues to challenge clinicians, especially when balancing effective anticoagulation with the risks of bleeding. During this live, interactive webcast, Dr. Gibson and Dr. Patel will explore novel therapeutic approaches, including the emerging role of Factor XIa inhibition. Through the expert-led discussions, real-world case scenarios, and the latest clinical data, participants will gain new perspectives on how to reduce residual stroke risk while improving safety profiles for high-risk patients.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In these mini-module episodes, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs to improve outcomes among patients.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.

Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
This video Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Activity Summary:
In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
In these mini-modules, expert faculty inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. By using clinical case scenarios, this activity clarifies clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Dr. Orlowski, Dr. Raje, and Dr. Voorhees lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
Clinical Viewpoints MF includes a curriculum that highlights the very latest clinical data in myelofibrosis. Slides are developed and updated throughout the year by leading MF expert physicians. All content is reviewed and approved by the Clinical Viewpoints MF Planning Committee.

Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. This case-based slide kit discusses the pathophysiology, burden diagnosis, current and future treatment strategies, risk stratification, adverse events associated with therapies as well as the importance of patient-centered care.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This clinical clip will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.